La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
uniQure Gestion
Gestion contrôle des critères 1/4
Le PDG uniQure's est Matt Kapusta, nommé en Dec2016, a un mandat de 7.67 ans. La rémunération annuelle totale est $ 6.58M, composée du salaire de 9.6% et des bonus 90.4%, y compris les actions et options de la société. détient directement 0.67% des actions de la société, d'une valeur de $ 2.21M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 6.9 ans.
Informations clés
Matt Kapusta
Directeur général
US$6.6m
Rémunération totale
| Pourcentage du salaire du PDG | 9.6% |
| Durée du mandat du directeur général | 7.8yrs |
| Propriété du PDG | 0.7% |
| Durée moyenne d'occupation des postes de direction | 1.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7yrs |
Mises à jour récentes de la gestion
Recent updates
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$285m |
| Mar 31 2024 | n/a | n/a | -US$297m |
| Dec 31 2023 | US$7m | US$635k | -US$308m |
| Sep 30 2023 | n/a | n/a | -US$228m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$6m | US$609k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$125m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$324m |
| Dec 31 2021 | US$5m | US$583k | US$330m |
| Sep 30 2021 | n/a | n/a | US$321m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | -US$139m |
| Dec 31 2020 | US$4m | US$585k | -US$125m |
| Sep 30 2020 | n/a | n/a | -US$166m |
| Jun 30 2020 | n/a | n/a | -US$136m |
| Mar 31 2020 | n/a | n/a | -US$124m |
| Dec 31 2019 | US$4m | US$548k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$105m |
| Jun 30 2019 | n/a | n/a | -US$103m |
| Mar 31 2019 | n/a | n/a | -US$92m |
| Dec 31 2018 | US$3m | US$502k | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$78m |
| Mar 31 2018 | n/a | n/a | -US$78m |
| Dec 31 2017 | US$4m | US$468k | -US$79m |
Rémunération vs marché: La rémunération totale de Matt ($USD 6.58M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.41M ).
Rémunération et revenus: La rémunération de Matt a augmenté alors que l'entreprise n'est pas rentable.
PDG
Matt Kapusta (52 yo)
7.8yrs
Titularisation
US$6,584,919
Compensation
Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 7.8yrs | US$6.58m | 0.67% $ 1.7m | |
| CFO, Principal Financial Officer & GM of Amsterdam Site | 3.3yrs | US$2.12m | 0.16% $ 385.4k | |
| Chief Business & Scientific Officer | less than a year | US$2.62m | 0.068% $ 168.7k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 1.3yrs | US$2.54m | 0.022% $ 55.5k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | no data | pas de données | pas de données | |
| Chief Technical Operations | less than a year | pas de données | pas de données | |
| Business Development Director | 16.3yrs | pas de données | pas de données | |
| Chief Corporate Affairs Officer | 2.5yrs | US$1.22m | pas de données | |
| Chief Medical Officer | 1.3yrs | pas de données | 0.24% $ 585.5k | |
| Vice President of Global Medical Affairs | no data | pas de données | pas de données |
1.9yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe de direction de QURE n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 9.7yrs | US$6.58m | 0.67% $ 1.7m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 10.1yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 4.3yrs | US$412.46k | 0.033% $ 81.3k | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Non-Executive Director | 8.3yrs | US$424.96k | 0.013% $ 33.0k | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Non-Executive Director | 7yrs | US$412.46k | 0.049% $ 120.7k | |
| Independent Non-Executive Director | 7yrs | US$424.96k | 0.049% $ 120.7k | |
| Independent Chairman of the Board | 6.3yrs | US$444.96k | 0.042% $ 102.9k | |
| Non-Executive Director | 5.9yrs | US$404.96k | 0.091% $ 224.4k |
7.0yrs
Durée moyenne de l'emploi
71yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de QURE sont considérés comme expérimentés (ancienneté moyenne 6.9 ans).